Overview

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Status:
Active, not recruiting

Trial end date:
2024-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborators:

Australasian Lung Cancer Trials Group
Central and Eastern European Oncology Group
Chinese Thoracic Oncology Group
Dutch Society of Physicians for Pulmonology and Tuberculosis
Fundación GECP
Intergroupe Francophone de Cancerologie Thoracique
Korean Cancer Study Group
National Cancer Institute (NCI), Naples
National Health and Medical Research Council, Australia
Spanish Lung Cancer Group
West Japan Oncology Group (WJOG)

Treatments:

Antibodies, Monoclonal
Durvalumab